A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS

Inclusion Criteria: * 18 to 90 years * NIHSS of 4 to 30 * Diagnosis of AIS within 24 hours after stroke symptoms onset Exclusion Criteria: * Treatement with approved drug during the current AIS * Pre-stroke disability * Imaging evidence of acute intracranial hemorrhage, intraparenchymal tumor, arteriovenous malformations, other central nervous system lesions that could increase bleeding risk, or aneurysm requiring treatment * Suspected subarachnoid hemorrhage * Seizure * Uncontrolled hypertension * INR \>1.7 and/or abnormal aPTT or platelet count \<100,000/mm3 * Blood glucose concentration \<50 mg/dL or \>400 mg/dL * Lactating or pregnant subjects or those planning to become pregnant during the study * Received anticoagulants and/or antiplatelet therapy and glycoprotein IIb/IIIa inhibitors within 48 hours * AIS, myocardial infarction, serious head trauma or major surgery within 90 days * Bleeding event within 21 days * Puncture of noncompressible vessels within 7 days * Severe hepatic, renal, and/or infectious disease